- Activity pressure is positive on the latest completed week.
- Latest weekly return ranks in the strongest part of its sector group.
VVY
AMS
Week ended 07 Aug 2026
Weekly Investor Report
Vivoryon Therapeutics N.V. · Healthcare · Biotechnology
Latest close
1.20 EUR
7.1%
latest week
Weekly setup
Weak trend
The weekly trend is not active. Price is -7.4% below the Trend Line and sits at 17.9% of its 52-week range. The latest completed week returned 7.1%, after a -14.3% four-week move. The latest news-sentiment score is 54/100.
Setup score
23
out of 100
Latest Close
1.20 EUR
7 Aug 2026
1W Return
7.1%
latest completed week
4W Return
-14.3%
short-term follow-through
12W Return
-4.4%
quarterly tape
Trend Breadth
3.8%
2 of 52 weeks active
Volume Ratio
1.1x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Next-week expectancy is negative at 40.83% based on similar historical setup states.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
7.1%
Latest completed week; four-week move -14.3%.
Indicator stack
2/68
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 40.83%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
News sentiment
54/100
4 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -7.4% below the Trend Line and sits at 17.9% of its 52-week range. The latest completed week returned 7.1%, after a -14.3% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 1.1x the 13-week average. Participation is around or above normal and provides reasonable confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.2112-week average 0.08
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure3/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.21Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -14.3% over four weeks, -4.4% over 12 weeks, and -16.9% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year2
Trend breadth3.8%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.35Latest activity-pressure read.
Pressure change142.2%Four-week change in activity pressure.
Leadership-25.23Latest relative-leadership reading.
RS change-93.5%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
A published fundamentals and factor snapshot is not available for this company.
No published fundamental snapshot is available for this company.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment54/100
Weighted news tone is neutral across 4 relevant articles.
1 positive · 3 neutral · 0 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-34.8%Distance below the 52-week high.
13-week volatility9.6%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher10 of 2616 weeks finished lower.
Best week+27.3%Week of 10 Jul.
Worst week-17.1%Week of 17 Jul.
Latest week+7.1%Week of 7 Aug.
Shape of recent returns
Strong gains2
Modest gains8
Flat weeks0
Modest losses10
Sharp losses6
Recent vol9.6%13-week weekly-return volatility.
Base vol5.9%52-week weekly-return volatility.
Up/down split20/32Count of positive and negative weeks in the 52-week window.
Average skew4.2% / -2.9%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorNL Healthcare
4-week rank2 / 3
Group average-12.9%
Trend breadth0.0%
Trend0.0%active weekly trend signals
MD66.7%positive activity pressure
RS0.0%positive relative leadership
Four-week leaders
IndustryNL Biotechnology
4-week rank1 / 2
Group average-17.5%
Trend breadth0.0%
Trend0.0%active weekly trend signals
MD50.0%positive activity pressure
RS0.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape23/100
Trend, activity pressure, participation, and risk combine to a 23/100 tape read.
Indicator analysis17/100Latest 12-week confirmation: trend 0/12, activity pressure 3/12, relative leadership 0/12.
Activity pressure 0.21; No reversal markers Next-Week ExpectancyNegative 40.83%Next-week expectancy is negative with a 40.83% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors50/100No published factor snapshot is available yet.
Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment54/100Weighted news tone is neutral across 4 relevant articles.
Vivoryon plans 2026 annual meeting for end of September Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 1.20 EUR | 7.1% | 1.30 EUR | 3.04 EUR | 0.35 | -25.23 | 212.1K | Off |
| 31 Jul 2026 | 1.12 EUR | -5.1% | 1.31 EUR | 3.11 EUR | 0.55 | -29.94 | 102.3K | Off |
| 24 Jul 2026 | 1.18 EUR | 1.7% | 1.32 EUR | 3.18 EUR | 0.15 | -26.11 | 159.1K | Off |
| 17 Jul 2026 | 1.16 EUR | -17.1% | 1.33 EUR | 3.26 EUR | -0.32 | -27.97 | 404.0K | Off |
| 10 Jul 2026 | 1.40 EUR | 27.3% | 1.34 EUR | 3.34 EUR | -0.82 | -13.04 | 846.3K | Off |
| 3 Jul 2026 | 1.10 EUR | 1.9% | 1.34 EUR | 3.41 EUR | -1.51 | -31.87 | 31.7K | Off |
| 26 Jun 2026 | 1.08 EUR | -1.8% | 1.36 EUR | 3.48 EUR | -1.37 | -32.22 | 22.4K | Off |
| 19 Jun 2026 | 1.10 EUR | -4.3% | 1.38 EUR | 3.55 EUR | -0.93 | -32.57 | 14.4K | Off |
| 12 Jun 2026 | 1.15 EUR | -7.3% | 1.40 EUR | 3.62 EUR | -0.74 | -30.26 | 90.6K | Off |
| 5 Jun 2026 | 1.24 EUR | -1.6% | 1.41 EUR | 3.70 EUR | -0.65 | -22.61 | 52.0K | Off |
| 29 May 2026 | 1.26 EUR | 1.2% | 1.42 EUR | 3.78 EUR | -0.59 | -21.53 | 336.8K | Off |
| 22 May 2026 | 1.25 EUR | -0.8% | 1.44 EUR | 3.87 EUR | -0.82 | -23.82 | 140.2K | Off |
| 15 May 2026 | 1.25 EUR | -2.0% | 1.45 EUR | 3.95 EUR | -0.89 | -21.26 | 122.4K | Off |
| 8 May 2026 | 1.28 EUR | -1.9% | 1.46 EUR | 4.04 EUR | -0.96 | -20.84 | 223.7K | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.